Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Obvius“
Suchtreffer
Begriffe & Kennungen
Carmustine medac (previously Carmustine Obvius) · 4.8 · MedDRA system organ Frequency Adverse reactions class Infections and infestations Not known Opportunistic infe
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Myelosuppression Myelosuppression is very common and begins 7-14 days of administration with recovery 42-56 da
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Neoplasms benign, Common Acute leukaemia, bone marrow malignant and unspecified dysplasia – following long-ter
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Nervous system disorders Very Ataxia, dizziness, headache. common Common Encephalopathy (high-dose therapy and
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Pulmonary fibrosis (with fatal outcome), pulmonary infiltration
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Pulmonary toxicity also manifested in the post-marketing phase as pneumonitis and interstitial lung disease. P
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Pulmonary toxicity has been observed in up to 30% of patients. In cases where pulmonary toxicity started early
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Rare Interstitial fibrosis (with lower doses). Gastrointestinal disorders Very Emetogenic potential. common Na
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Renal and urinary Rare Renal toxicity. disorders Reproductive system and Rare Gynecomastia. breast disorders N
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Renal toxicity Renal toxicity is rare, but occurs for cumulative doses < 1,000 mg/m2.
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Respiratory, thoracic and mediastinal disorders
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Summary of the safety profile The table includes adverse reactions that were presented during treatment with t
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · The following table includes adverse reactions of carmustine listed by MedDRA system organ class and frequency
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Vascular disorders Very Phlebitis. common Rare Veno-occlusive disease (high-dose therapy). Respiratory, thorac
Eintrag öffnenCarmustine medac (previously Carmustine Obvius) · 4.8 · Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1 000 to <1/100); Rare (≥1/10 000 to < 1/1 000); V
Eintrag öffnen